Literature DB >> 2930691

Breast cancer, prostaglandins and patient survival.

A Bennett1, I F Stamford, D A Berstock, F Dische, L Singh, R P A'Hern.   

Abstract

Prostaglandins may have both undesirable and desirable effects in malignant disease. Their possible roles in breast cancer were studied by examining the relationships between different variables and the amounts of prostaglandin-like material (PG-LM) extracted from 141 breast carcinomas. Univariate analysis indicates a direct correlation with patient age and menopausal status, with a greater yield from cancers of post- compared with pre-menopausal women. Tumours up to 2 cm diameter yielded more PG-LM than those measuring greater than 2-5 cm. Although there was also a direct correlation with bone metastasis near to the time of surgery, this was because no positive bone scans occurred in patients whose tumours yielded little total PG-LM (less than 16 ng PGE2 equivalents per g tissue). Since tumour PG-LM did not predict later spread to bone, and yields of greater than 16 ng g-1 were similar in the positive and negative bone scan groups, tumour PG-LM appears to be unimportant for skeletal metastasis. There was no obvious relationship of tumour PG-LM to the grade of malignancy, tumour type, amounts of fibrous tissue (and therefore malignant cells), invasion of blood vessels and lymphatics or presence of plasma cells. Multivariate analysis indicates that disease-free survival is longest with an intermediate production of tumour total PG-LM. Of the 82 patients now dead, the cause was attributed to metastatic disease in 69 cases. No relationship of PG-LM to the length of survival was seen with univariate or multivariate analysis. However, when just the post-menopausal patients who died within the first 3 postoperative years were analysed, there was a highly significant inverse correlation between the tumour total PG-LM and the time to death. The reason(s) for these different findings on overall survival compared with just the patients who died are not understood, but the results may indicate that one or more other variables must co-exist with a high tumour PG-LM to hasten death.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2930691      PMCID: PMC2247010          DOI: 10.1038/bjc.1989.56

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  A computer program for comparing K samples with right-censored data.

Authors:  E T Lee; M M Desu
Journal:  Comput Programs Biomed       Date:  1972-11

2.  Human breast carcinomas release prostaglandin-like material into the blood.

Authors:  I F Stamford; J MacIntyre; A Bennett
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1980

3.  The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4).

Authors:  E R Fisher; R M Gregorio; B Fisher; C Redmond; F Vellios; S C Sommers
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

4.  Prostaglandins: their disappearance from and release into the circulation.

Authors:  S H Ferreira; J R Vane
Journal:  Nature       Date:  1967-12-02       Impact factor: 49.962

5.  Failure of indomethacin to reduce hypercalcemia in patients with breast cancer.

Authors:  R C Coombes; A M Neville; P K Bondy; T J Powles
Journal:  Prostaglandins       Date:  1976-12

6.  Prostaglandin E2 and gastric acid secretion in man.

Authors:  A Bennett; I F Stamford; W G Unger
Journal:  J Physiol       Date:  1973-03       Impact factor: 5.182

7.  Breast cancer, prostaglandins, and bone metastases.

Authors:  A Bennett; A M McDonald; J S Simpson; I F Stamford
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

8.  Prostaglandins as mediators of hypercalcemia associated with certain types of cancer.

Authors:  H W Seyberth; G V Segre; J L Morgan; B J Sweetman; J T Potts; J A Oates
Journal:  N Engl J Med       Date:  1975-12-18       Impact factor: 91.245

9.  Prostaglandins and breast cancer.

Authors:  A Bennett; E M Charlier; A M McDonald; J S Simpson; I F Stamford; T Zebro
Journal:  Lancet       Date:  1977-09-24       Impact factor: 79.321

10.  Promotion of growth of tumour cells in acutely inflamed tissues.

Authors:  H A Van Den Brenk; M Stone; H Kelly; C Orton; C Sharpington
Journal:  Br J Cancer       Date:  1974-09       Impact factor: 7.640

View more
  5 in total

1.  Prognostic value of prostaglandin F2 alpha concentrations in breast carcinoma.

Authors:  P A van Dam; I B Vergote; G M Laekeman; G H Keersmaeckers; F L Uyttenbroeck; A G Herman
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

Review 2.  Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas.

Authors:  Maki Mitsuhashi; Jianguo Liu; Shanjin Cao; Xiaoyan Shi; Xiaojing Ma
Journal:  J Leukoc Biol       Date:  2004-05-03       Impact factor: 4.962

3.  Fatty acid metabolites in rapidly proliferating breast cancer.

Authors:  Joseph T O'Flaherty; Rhonda E Wooten; Michael P Samuel; Michael J Thomas; Edward A Levine; L Douglas Case; Steven A Akman; Iris J Edwards
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

4.  Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts.

Authors:  N Matsumoto-Taniura; K Matsumoto; T Nakamura
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

Review 5.  Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update.

Authors:  Mariana Segovia-Mendoza; Janice García-Quiroz; Lorenza Díaz; Rocío García-Becerra
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.